Abstract
Thirty-five evaluable patients with advanced adenocarcinoma of the pancreas were treated with piroxantrone at a dose of 150 mg/m2 intravenously every 21 days. No objective responses were observed (95% confidence interval 0%-10%). Toxicities of grade > or = 3 were primarily hematologic and were seen in 28 patients. Piroxantrone is inactive in pancreatic cancer and no further investigation of this agent in this tumor is recommended.
Publication types
-
Clinical Trial
-
Clinical Trial, Phase II
-
Research Support, U.S. Gov't, P.H.S.
MeSH terms
-
Adenocarcinoma / drug therapy*
-
Adenocarcinoma / secondary
-
Adult
-
Aged
-
Anthraquinones / adverse effects
-
Anthraquinones / therapeutic use*
-
Antineoplastic Agents / adverse effects
-
Antineoplastic Agents / therapeutic use*
-
Female
-
Humans
-
Male
-
Middle Aged
-
Pancreatic Neoplasms / drug therapy*
-
Pyrazoles / adverse effects
-
Pyrazoles / therapeutic use*
Substances
-
Anthraquinones
-
Antineoplastic Agents
-
Pyrazoles
-
piroxantrone